Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity-Reference-Cited by-同舟云学术

Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity

Published:2017-03-10 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Bao Bin,Mitrea Cristina,Wijesinghe Priyanga,Marchetti Luca,Girsch Emily,Farr Rebecca L.,Boerner Julie L,Mohammad Ramzi,Dyson Greg,Terlecky Stanley R.,Bollig-Fischer Aliccia

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep44125.pdf

Reference31 articles.

1. Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502 doi: 10.1001/jama.295.21.2492 (2006).

2. Korsching, E. et al. Basal carcinoma of the breast revisited: an old entity with new interpretations. Journal of Clinical Pathology 61, 553–560 doi: 10.1136/jcp.2008.055475 (2008).

3. Chen, L. et al. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Research and Treatment 157, 545–554 doi: 10.1007/s10549-016-3825-9 (2016).

4. Phipps, A. I. et al. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiology Biomarkers & Prevention 20, 454–463 doi: 10.1158/1055-9965.EPI-10-0974 (2011).

5. Kreike, B. et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Research 9, 1 doi: 10.1186/bcr1771 (2007).

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer;European Journal of Medicinal Chemistry;2024-10

2. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials;Medical Oncology;2024-06-12

3. Regulación de la angiogénesis por antioxidantes en el cáncer de mama triple negativo;Journal of Basic Sciences;2024-04-30

4. TGF-β, EMT, and resistance to anti-cancer treatment;Seminars in Cancer Biology;2023-12

5. Curdlan/Clay Nanocomposite-Reinforced Alginate Beads as Drug Carriers;Journal of Polymers and the Environment;2023-09-12